NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, where the company will highlight its novel biologics platform. The event is being held May 13-17, 2024 at the Omni Hotel at the Seaport, Boston, MA.

Following the recent launch of its AI-driven drug discovery services in the US and Europe and the rollout of STB LaunchPad, Syntekabio's versatile technology platform for small molecule drug  candidate generation, the company is excited to showcase its in-silico biologics discovery capabilities with Neo-ARS, its cutting-edge AI platform for personalized or universal neoantigenprediction, so-called tumor-specific cancer vaccines, as well as Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains.

Jonathan Witztum, PhD, Chief Technology Officer at Syntekabio USA Inc., commented: “PEGS Boston is an excellent platform for us to present our in-silico biologics platform and our comprehensive set of AI-driven solutions for drug discovery. We look forward to engaging with leading biologics experts and discussing how our innovative technologies can positively impact therapeutics development and help to bring novel, highly effective solutions to patients.

Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications.